N-n-pentyl-N-propylamine | 20193-22-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-n-pentyl-N-propylamine
• 英文别名: N-n-propylaminopentane；N-propylpentylamine；pentyl-propyl-amine；1-Propylamino-pentan；Pentyl-propyl-amin；N-propyl-1-pentylamine；N-Propylpentanamine；N-propylpentan-1-amine
• CAS: 20193-22-0
• 化学式: C₈H₁₉N
• mdl: MFCD11141195
• 分子量: 129.246
• InChiKey: GFAQQAUTKWCQHA-UHFFFAOYSA-N

物化性质

• 保留指数：
  947

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-n-pentyl-N-propylamine 、 2-氯-N,N-二甲基乙胺 在 xylene 作用下， 生成 N,N-dimethyl-N'-pentyl-N'-propyl-ethylenediamine
  参考文献：
  名称：

  Derivatives of Dimethylaminoethanol and Dimethylaminoethylamine

  摘要：

  DOI：

  10.1021/ja01125a050
• 作为产物：
  描述：

  戊腈 在 copper chromite 、 乙醚 、 氨 、 镍 作用下， 125.0~180.0 ℃ 、12.26 MPa 条件下， 生成 N-n-pentyl-N-propylamine
  参考文献：
  名称：

  Preparation of Certain Amines

  摘要：

  DOI：

  10.1021/ja01267a081

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• [EN] METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE SYMPTÔMES NEUROLOGIQUES ASSOCIÉS À DES MALADIES LYSOSOMALES
  申请人：GENZYME CORP

  公开号：WO2021156769A1

  公开（公告）日：2021-08-12

  Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.

  提供了用于治疗或预防与溶酶体贮积病等相关的神经症状和疾病的方法。这些方法包括增强受试者大脑内的神经连接、增加大脑组织体积，或者预防或延迟受试者大脑组织体积的丧失。还提供了用于监测神经疾病的进展或退化，或评估与溶酶体贮积病相关的神经疾病的发作的方法，其中测量了受试者的大脑组织体积。
• [EN] METHODS FOR TREATING PROTEINOPATHIES<br/>[FR] PROCÉDÉS DE TRAITEMENT DE PROTÉINOPATHIES
  申请人：GENZYME CORP

  公开号：WO2016145046A1

  公开（公告）日：2016-09-15

  This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.

  这份披露涉及一种治疗受试者蛋白病的方法，该方法包括向受试者施用有效量的环丙胺化合物。该披露还涉及一种减少、逆转或预防被诊断为患有蛋白病或有患蛋白病风险的受试者组织中蛋白聚集物积累的方法，该方法包括向受试者施用有效量的环丙胺化合物。还披露了一种包含环丙胺化合物的药物组合物，用于上述方法。蛋白病可能是突触核蛋白病或tau蛋白病，如帕金森病、阿尔茨海默病或带有Lewy小体的痴呆症。
• [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS<br/>[FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009112439A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。
• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：REMYND NV

  公开号：WO2015140130A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)的化合物或其立体异构体、对映体、消旋体或互变异构体，其中R1、R2、R3、L1、L2、L3、L4、L5和n的含义与权利要求和说明中定义的含义相同。本发明还涉及包含这些化合物的组合物，特别是药物，以及利用这些化合物和组合物预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错折性疾病的用途。